TABLE 1.

In vivo studies of the effects of LF in different infection models

LF administration	Source(s)	Target	Reference
Oral
20 mg/kg	bLF protein	Entamoeba histolytica	36
20–25 mg/mouse	bLF protein	Mycobacterium tuberculosis	37
5 or 100 mg/mouse	bLF protein	Salmonella enterica serovar Typhimurium	38
10 mg/kg	hLF protein	Listeria monocytogenes	39
62.5 mg/mouse	bLF protein	Influenza virus	40
0.5 g/kg, 7 days	bLF protein	Candida albicans	41
0.5–2%, 7 days	bLF protein	Fecal microflora	5
2%, 7 days	bLF protein	Clostridium	6
2 mg/dose	hLF protein peptide	Colitis	27
200 mg/kg rats	bLF protein	Colitis	42
2%, 12 days	bLF protein	IBD	24
i.v.
100 mg/ml, 2 or 12 days	hLF and bLF	LPS	19
10 mg, 2 h, 24 h	bLF protein	Escherichia coli	35
10 mg/mouse	bLF protein	E. coli	43
0.5 mg/mouse	bLF protein	E. coli	44
250 μg/body wt	hLF protein	LPS	45
10 mg/mouse	hLF and bLF protein	E. coli	50
10 mg/g body wt	bLF protein	E. coli	47
10 mg/mouse	bLF protein	Listeria monocytogenes	46
10 mg/mouse	bLF protein	E. coli	48
Other
Oral and i.v., 0.04 to 40 mg/kg	hLF peptide	S. aureus	49
Ileal, 2 mg/loop	bLF protein	Cholera toxin	48
Oral and i.v., 100 mg/ml	hLF peptide	S. aureus	10